Clinical Trials
9 articles
Pfizer's obesity drug shows potential for monthly dosing
Mid-stage study data reveals Pfizer's experimental obesity drug, berobenatide, could achieve significant weight loss with a groundbreaking monthly dosing schedule, a stark contrast to current weekly o
Retatrutide's Triple Hormone Action Aims to Revolutionize Obesity Treatment
Patients on the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks in the latest study, a result mirroring bariatric surgery, according to the South Florida Reporter
AI Drug Development Surges: In Silico Trials Market Grows Dramatically
Biotech firm Insilico Medicine used artificial intelligence to discover a novel drug candidate for idiopathic pulmonary fibrosis (IPF) and advance it to Phase I clinical trials in under 30 months, acc
Phage therapy adoption hurdles: Regulatory and clinical challenges.
By 2050, antimicrobial resistance (AMR) is projected to cause 10 million deaths worldwide annually.
BioNTech, Pfizer Share Bispecifics Data at ASCO
BioNTech's BNT142 achieved 7 RECIST 1.
Bristol Myers Squibb shows strong multiple myeloma data
In a significant development for multiple myeloma patients, Bristol Myers Squibb's mezigdomide triplet demonstrated a median progression-free survival of 18 months, more than doubling the 8.
Bepirovirsen data shows functional cure in 19% of hepatitis B patients
An experimental hepatitis B treatment achieved a 'functional cure' in nearly 1 in 5 patients during its pivotal Phase 3 studies, a significant stride against a chronic viral infection that afflicts mi
New drug Bepirovirsen functionally cures hepatitis B in some patients
In two late-stage clinical trials, GSK's experimental drug Bepirovirsen achieved a functional cure for 19% of patients with chronic hepatitis B, a disease that has long resisted effective treatment.
Merck Halts Parkinson's Drug Program After Phase 3 Setback
Merck's Parkinson's drug, preladenant, was discontinued in 2026 after Phase 3 trials showed it was no more effective than a placebo.